Associate Director, Product Management
Wednesday, May 11 | 11:40 AM PDT
Solution Focus Roundtable 2:
Beyond MRD: What’s NeXT for ctDNA?
- MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain
- We’ll discuss some of the most pressing needs in the liquid biopsy space, including earlier detection of disease recurrence, utility in more disease indications, and at earlier stages of disease
- Other considerations such as clinical trial needs for patient enrichment, screening/enrollment, and surrogate endpoint analysis as well as the necessity for higher resolution variant tracking will be explored